Roch Doliveux - UCB SA Insider

UCB SA -- USA Stock  

USD 41.50  0.00  0.00%

Chairman of the Executive Committee, CEO, Executive Director

Dr. Roch Doliveux has served as Executive Director of UCB S.A. since January 1 2015. He was Chief Executive Office and Chairman of the Executive Committee of the Company until January 1 2015. He is Doctor in Veterinarian Medicine from MaisonsAlfort Mr. Doliveux is also Laureate of the Faculty of Medicine Creteil and holds a Masters of Business Administration from INSEAD with distinction. He joined the pharmaceutical industry early first at CibaGeigy in Switzerland in Peru and in France and then at ScheringPlough Corporationrationration in various positions including President of ScheringPlough International. Then Roch Doliveux joined the Pierre Fabre group a Chief Executive Officer of Pierre Fabre Pharmaceuticals
Age: 58  Chairman Since 2015  Ph.D    
32 2 559 99 99
Doliveux joined UCB in October 2003 as Director General of the Pharma Sector and Deputy Chairman of the Executive Committee. He became CEO and Chairman of the Executive Committee of UCB on January 1, 2005. He is a member of the Board of Directors of UCB, Member of the Board of Stryker Corporationrationrationration in the United States, as well as a member of the Board of the European Federation of Pharmaceutical Association, the Innovative Medicines Initiative which is a publicprivate partnership between the European Union and EFPIA, WELBIO, the INSEAD International Council and Chairman of the Caring Entrepreneurship Fund . He was awarded the Doctor Honoris Causa degree of the University of Liege in October 2011.

Roch Doliveux Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 5.76 % which means that it generated profit of $5.76 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 13.02 % meaning that it generated $13.02 on every $100 dollars invested by stockholders.
The company has accumulated 1.97 B in total debt with debt to equity ratio (D/E) of 28.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. UCB SA has Current Ratio of 1.09 suggesting that it may not have the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. UCB SA was founded in 1928 and is headquartered in Brussels, Belgium. UCB SA is traded on OTC Market in USA.UCB SA (UCBJY) is traded on OTC Market in USA. It is located in All?e de la Recherche, 60 and employs 7,500 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add UCB SA to your portfolio

Top Management

UCB SA Leadership Team
Pascale Richetta, President
Detlef Thielgen, CFO
Kay Davies, Director
Anna Richo, EVP
Gerhard Mayr, Chairman
Cyril Janssen, Director
Cedric Rijckevorsel, Director, CFA
JeanChristophe Tellier, Chairman
Arnoud Calesberg, Director
Mark McDade, COO
Xavier Michel, President
Bharat Tewarie, President, MBA
Roch Doliveux, Chairman, Ph.D
Norman Ornstein, Director
Jeff Wren, President
JeanPierre Kinet, Director, Ph.D
Antje Witte, VP
Alice Dautry, Director
Harriet Edelman, Director, MBA
Ulf Wiinberg, Director
Thomas McKillop, Director, Ph.D
Charl Zyl, President
Fabrice Enderlin, President
Pierre Gurdjian, Director
Ismail Kola, EVP, Ph.D
Emmanuel Caeymaex, President
Evelyn Bergendal, Executive
Iris LoewFriedrich, President, Ph.D
CharlesAntoine Janssen, Director
Albrecht Graeve, Director

Stock Performance

UCB SA Performance Indicators